Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Precision Optics (POCI): Analyzing the Path to an $8 Target and +61% Upside

Precision Optics (POCI): Analyzing the Path to an $8 Target and +61% Upside

Key Takeaways

  • The central target is $8 per share, which implies a move of roughly 61% above the latest price near $4.97.
  • This $8 figure is not an analyst consensus. Precision Optics has only one published price target, so the objective rests on that single target and the stock's prior all-time-high zone near $7.85.
  • Precision Optics is a micro-cap designer and manufacturer of advanced optical and illumination systems for medical, defense, and industrial customers, and it remains unprofitable.
  • Supporting factors include record fiscal 2026 revenue growth, raised guidance, positive adjusted EBITDA late in the year, and a strengthened balance sheet.
  • The biggest risks are an expected satellite-customer revenue decline, a projected fiscal 2027 adjusted EBITDA loss, customer concentration, and very thin analyst and trading coverage.

How the $8 Target Came Into View

Precision Optics Corporation, Inc. (POCI) does not attract broad analyst attention. A single firm, Lucid Capital Markets, started coverage on May 18, 2026, with a Buy rating and an $8.00 objective, describing the company as an undervalued growth name in medical and defense optics. With only one published target available, the $8 level here draws from that source plus the stock’s earlier peak near $7.85 rather than any averaged consensus. It functions as a reference point anchored to both the published call and a prior technical high, and readers should treat it with that single-source limitation in mind. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where the Stock Stands Today and What Reaching the Target Would Require

Shares trade near $4.97, roughly midway in a 52-week range of $3.55 to $6.15. Closing the gap to $8 would mean an advance of about 61%, a sizable move for any micro-cap with a market value around $50 million. The route would likely involve first reclaiming the 52-week high near $6.15, then surpassing the all-time high near $7.85. On the fundamentals side, that would call for turning strong revenue growth into consistent profitability and positive free cash flow, maintaining defense and aerospace momentum, and navigating the revenue step-down management has already flagged from a satellite customer.

Factors That Could Help Drive Shares Higher

Fiscal 2026 was strong, with revenue climbing roughly 65% to about $31.5 million and a five-year revenue CAGR near 24%. Management lifted full-year guidance, and the company posted positive adjusted EBITDA in the second half alongside better gross margins and yields. An oversubscribed $10 million raise left the balance sheet with net cash and modest debt, giving more room for scaling and upgrades. Growth in defense and aerospace, including satellite work and new programs, adds a second leg beyond medical endoscopes and micro cameras. The lone Buy-rated $8 target reflects an optimistic view that this small, vertically integrated optics maker can re-rate as it grows.

Obstacles That Could Keep the Target Out of Reach

The company has not yet shown sustainable profits: fiscal 2026 produced a net loss of about $3.6 million, negative EPS, and a fifth straight year of negative free cash flow. Gross margins have narrowed from the mid-30s into the high teens. Management has guided to a roughly 40% sequential revenue drop in the first quarter of fiscal 2027 tied to the satellite customer, with further reduction expected in the second quarter and an adjusted EBITDA loss for the full year. Customer concentration and limited disclosure raise execution questions, while repeated share issuance over five years has diluted holders. Thin coverage, low trading volume, and a five-year share-price lag versus the broader market also weigh on sentiment.

Key Technical Levels to Watch

The 52-week high near $6.15 stands as the first notable resistance on any climb toward $8, followed by the all-time high around $7.85, which serves as both a psychological and structural barrier. Support appears near the recent $4.30 to $4.50 area, with the 52-week low of $3.55 as a deeper floor. A sustained move above $6.15 on rising volume would mark an important breakout, while any failure to hold recent lows could leave shares range-bound.

Time Horizon and Items Worth Monitoring

Analyst targets typically look out about 12 months, though a single-target stock offers limited confirmation of that timeframe. Investors should track quarterly results and guidance, especially the satellite-program revenue transition, any progress toward positive EBITDA and free cash flow, new defense and medical wins, and whether additional analysts begin coverage. Balance-sheet health and potential future capital raises also matter given the company’s cash-burn history. From what I see, these quarterly updates will be the clearest signals.

Using AI Daily Buy/Sell Signals for Micro-Cap Monitoring

I have found Tickeron’s AI Daily Buy/Sell Signals helpful when following thinly covered names like POCI. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a micro-cap with limited traditional coverage, it offers a way to surface ideas and track trends more efficiently alongside fundamental work. Signals are informational and work best when combined with other research and personal risk considerations.

Final Assessment

The $8 objective remains a reference drawn from one Lucid Capital Markets target and the stock’s prior peak near $7.85 rather than any broad consensus. It would require a substantial advance of about 61% from roughly $4.97. The main supports are record revenue growth, raised guidance, a late-year EBITDA inflection, a stronger balance sheet, and defense momentum. The main hurdles are ongoing losses, negative free cash flow, the guided satellite revenue decline and expected fiscal 2027 EBITDA loss, customer concentration, and very limited coverage. Watching quarterly results, the satellite transition, and any move toward profitability will be essential before assessing how realistic the distance to $8 really is.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: POCI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


POCI's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for POCI moved out of overbought territory on November 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 17 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on POCI as a result. In 104 of 130 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for POCI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 46 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

POCI moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where POCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for POCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 21 of 27 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.

Following a +4.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where POCI advanced for three days, in 113 of 165 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

POCI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 110 of 150 cases where POCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.614) is normal, around the industry mean (4.964). P/E Ratio (-11.302) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.113) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. POCI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -5%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 7%. STXS experienced the highest price growth at 19%, while RGNT experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 16%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 54
Price Growth Rating: 51
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 20 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Industry
N/A
Address
22 East Broadway
Phone
+1 978 630-1800
Employees
90
Web
https://www.poci.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.